TACE联合替吉奥及阿帕替尼在晚期胃癌中的应用  

TACE Combined With Oral Administration of Tegafur and Apatinib in the Treatment of Advanced Gastric Cancer

作　　者：韩宗宏[1] 何忠明[1] 陆一峰[1] 陈文华[1] 王草叶[1] 盛晔[1] 黄渊全[1] 王祁[1] 

机构地区：[1]常州市第一人民医院介入放射科,江苏常州213003

出　　处：《中国卫生标准管理》2016年第20期87-89,共3页China Health Standard Management

摘　　要：目的探讨经动脉化疗栓塞术（TACE）联合替吉奥及阿帕替尼治疗晚期胃癌的近期疗效和安全性。方法对我科2015年1-12月收治的26例晚期胃癌患者进行TACE联合替吉奥及阿帕替尼治疗。TACE（吡柔比星20 mg/m2＋奥沙利铂100 mg/m2＋碘油）,术后第3 d开始服用阿帕替尼（250 mg,1次/d）,术后第8 d口服替吉奥（40 mg/m2,2次/d,d8-d21）,采用m RECIST标准进行疗效评价。结果随访6-18个月,2个疗程后CR 4例,PR 12例,SD 7例,PD 3例,RR 88.46%,中位生存期15.28个月,无严重并发症发生。结论 TACE联合替吉奥及阿帕替尼治疗晚期胃癌近期疗效肯定,不良反应发生率低,远期疗效待进一步研究。Objective To investigate the efficacy and safety of the transcatheter arterial chemoembolization（TACE）combined with oral administration of tegafur and apatinib in treating advanced gastric cancer. Methods Twenty-six patients with advanced gastric cancer patients in our department were treated by TACE combined with oral administration of tegafur and apatinib from January to December 2015. TACE（pirarubicin 20 mg/m2＋oxaliplatin 100 mg/m2＋lipiodol）,the third postoperative day taking apatinib（250 mg,once daily）,postoperative eighth day of oral tegafur（40 mg/m2,twice daily,d8- d21）,using modified RECIST standards for efficacy evaluation. Results The follow-up period was six to eighteen months,of twenty-six patients complete remission（CR）was seen in four,partial remission（PR）in twelve,stable disease（SD）in seven and progressive disease（PD）in three after two courses. The remission rate（RR）was 88.46% with a median survival of 15.28 months and no serious complications occurred. ConclusionTACE combined with oral administration of tegafur and apatinib in treating advanced gastric is effective in the near future with low incidence of adverse reactions and is worthy of further promotion,but the long-term efficacy need further study.

关 键 词：化疗栓塞 替吉奥 阿帕替尼 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]